“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities, the industry must address key hurdles in preclinical models, patient selection, ADC design, and cross-disciplinary communication to accelerate the next wave of safer, more effective ADCs.

The 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.

With insights from influential leaders such as AbbVie, AstraZeneca, Daiichi Sankyo, Genentech, Iksuda, J&J, MacroGenics and more, this is your opportunity for in-depth discussions and world class presentations on maximizing the translational relevance of in vivo and in vitro studies, mitigating toxicities to extend clinical dose escalations, optimizing dosing regimens, navigating regulatory expectations for toxicity models and more…